Timing of high-efficacy therapy initiation in multiple sclerosis: a multicenter real-world analysis from Argentina.
Early initiation of high-efficacy therapies (HETs) in relapsing-remitting multiple sclerosis (RRMS) is associated with improved long-term outcomes, yet real-world treatment trajectories may not reflect this paradigm. We aimed to quantify delays in diagnosis and treatment initiation in RRMS and assess whether these diff...